Renal Osteodystrophy-Time for Common Nomenclature

Overview

Journal Curr Osteoporos Rep

Publisher Current Science

Specialties Endocrinology
Orthopedics

Date 2017 May 4

PMID 28466454

Citations 5

Authors

Susan M Ott

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The term renal osteodystrophy has been used to describe a wide variety of bone problems facing patients with chronic kidney disease (CKD). Here, we review the history of the use of this term.

Recent Findings: Bone disease resulting from CKD was first noticed in 1890. The term "renal osteodystrophy" was used to define the bone disease in 1942. Since then, important discoveries have increased our knowledge of the complexities of bone physiology in these patients. At the same time, secular changes in the disease have occurred. The terms used to describe the bone histological findings have changed as well, reflecting new understanding of the physiological processes. However, since different investigators used the terms in different ways, the need to standardize the nomenclature has become increasingly important. Ongoing international collaboration about nosography will allow more optimal communication among scientists and clinicians as we continue to make new discoveries.

Citing Articles

Application of artificial intelligence to chronic kidney disease mineral bone disorder.

Lederer E, Sobh M, Brier M, Gaweda A Clin Kidney J. 2024; 17(6):sfae143.

PMID: 38899159 PMC: 11184350. DOI: 10.1093/ckj/sfae143.

Osteocytic Sclerostin Expression as an Indicator of Altered Bone Turnover.

Huybrechts Y, Evenepoel P, Haarhaus M, Cavalier E, Dams G, Van Hul W Nutrients. 2023; 15(3).

PMID: 36771305 PMC: 9921466. DOI: 10.3390/nu15030598.

Renal osteodystrophy: A historical review of its origins and conceptual evolution.

Eknoyan G, Moe S Bone Rep. 2022; 17:101641.

PMID: 36466709 PMC: 9713281. DOI: 10.1016/j.bonr.2022.101641.

Prevalence of Renal Osteodystrophy and its Related Factors among End-stage Renal Disease Patients Undergoing Hemodialysis: Report from Imam Reza Referral Hospital of Medical University of Kermanshah, Iran.

Seyedzadeh A, Tohidi M, Golmohamadi S, Omrani H, Seyedzadeh M, Amiri S Oman Med J. 2022; 37(1):e335.

PMID: 35136664 PMC: 8804157. DOI: 10.5001/omj.2021.120.

Chronic kidney disease-related osteoporosis is associated with incident frailty among patients with diabetic kidney disease: a propensity score-matched cohort study.

Chao C, Wang J, Huang J, Chan D, Hung K, Chien K Osteoporos Int. 2020; 31(4):699-708.

PMID: 32103279 DOI: 10.1007/s00198-020-05353-9.

References

Malluche H, Monier-Faugere M . Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings. Clin Nephrol. 2006; 65(4):235-42. DOI: 10.5414/cnp65235. View

Gonzalez E, Lund R, Martin K, McCartney J, Tondravi M, Sampath T . Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int. 2002; 61(4):1322-31. DOI: 10.1046/j.1523-1755.2002.00258.x. View

Lotinun S, Sibonga J, Turner R . Evidence that the cells responsible for marrow fibrosis in a rat model for hyperparathyroidism are preosteoblasts. Endocrinology. 2005; 146(9):4074-81. DOI: 10.1210/en.2005-0480. View

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

Ott S . Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol. 2008; 3 Suppl 3:S151-6. PMC: 3152285. DOI: 10.2215/CJN.04301206. View

LIGHTWOOD R . Renal Rickets. Proc R Soc Med. 2009; 25(4):418-20. PMC: 2183816. View

ELLIS H, Pierides A, Feest T, Ward M, Kerr D . Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis. Clin Endocrinol (Oxf). 1977; 7 Suppl:31s-38s. DOI: 10.1111/j.1365-2265.1977.tb03359.x. View

Liu E, Martins J, Raimann A, Chae B, Brooks D, Jorgetti V . 1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression. J Bone Miner Res. 2016; 31(5):929-39. PMC: 4862933. DOI: 10.1002/jbmr.2783. View

Parfitt A, Drezner M, Glorieux F, Kanis J, MALLUCHE H, Meunier P . Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2(6):595-610. DOI: 10.1002/jbmr.5650020617. View

10.

Sherrard D, Baylink D, Wergedal J, Maloney N . Quantitative histological studies on the pathogenesis of uremic bone disease. J Clin Endocrinol Metab. 1974; 39(1):119-35. DOI: 10.1210/jcem-39-1-119. View

11.

Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K . Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69(11):1945-53. DOI: 10.1038/sj.ki.5000414. View

12.

Malluche H, Blomquist G, Monier-Faugere M, Cantor T, Davenport D . High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis. J Am Soc Nephrol. 2015; 26(10):2534-44. PMC: 4587691. DOI: 10.1681/ASN.2014070686. View

13.

Drueke T, Massy Z . Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016; 89(2):289-302. DOI: 10.1016/j.kint.2015.12.004. View

14.

Slatopolsky E, Bricker N . The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int. 1973; 4(2):141-5. DOI: 10.1038/ki.1973.92. View

15.

Dempster D, Compston J, Drezner M, Glorieux F, Kanis J, Malluche H . Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2012; 28(1):2-17. PMC: 3672237. DOI: 10.1002/jbmr.1805. View

16.

Sherrard D, Hercz G, Pei Y, Maloney N, Greenwood C, Manuel A . The spectrum of bone disease in end-stage renal failure--an evolving disorder. Kidney Int. 1993; 43(2):436-42. DOI: 10.1038/ki.1993.64. View

17.

Ott S, Maloney N, Coburn J, Alfrey A, Sherrard D . The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. N Engl J Med. 1982; 307(12):709-13. DOI: 10.1056/NEJM198209163071202. View

18.

Slatopolsky E, Caglar S, Gradowska L, Canterbury J, Reiss E, Bricker N . On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int. 1972; 2(3):147-51. DOI: 10.1038/ki.1972.84. View

19.

Calvi L, Sims N, Hunzelman J, Knight M, Giovannetti A, Saxton J . Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest. 2001; 107(3):277-86. PMC: 199196. DOI: 10.1172/JCI11296. View

20.

Fang Y, Ginsberg C, Sugatani T, Monier-Faugere M, Malluche H, Hruska K . Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int. 2013; 85(1):142-50. PMC: 3836911. DOI: 10.1038/ki.2013.271. View